NCT06593743 - The Safety and Dose Response to Single Anal Doses of NRL001 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

July 31, 2004

Study Completion Date

November 12, 2013

Conditions

Faecal Incontinence

Interventions

DRUG

Perianal NRL001 Gel 3 strengths

A single application of 0.3%, 1.0%, 3.0% NRL001 gel in stepwise dose ascending fashion.

DRUG

Intraanal NRL001 Gel 2 strengths

A single application of 3.0% or 1.0% Gel

DRUG

Intrarectal NRL001 Gel

A single application of 1.0% Gel

DRUG

NRL001: 10mg suppository

NRL001 10mg suppository applied to rectum.

Trial Locations (1)

University Hospital - Queens Medical Centre, Nottingham